在患有HFpEF的患者中,同情性缩后左心室结构和功能:心声回声9年长期随访:心声回声9年长期随访
Alexander Vogt1, Alexander Plehn1,2, Carlo Atti3
1Department of Internal Medicine III, University Hospital Halle (Saale), Halle (Saale), Germany.
Frontiers in cardiovascular medicine
|June 26, 2024
概括
脏缺血 (RDN) 可能有助于通过减少心脏重塑来逆转心力衰竭,而不仅仅是血压. 这项长期研究表明,RDN可以改善HFpEF标志物和心脏结构.
科学领域:
- 心脏病学 心脏病学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 医疗器械 医疗器械
背景情况:
- 高血压是心脏重塑和左心室缩的关键风险因素,增加心血管风险,导致心力衰竭与保留射出小部分 (HFpEF).
- 同情性缩 (RDN) 是一种可以长期降低血压的程序.
- 对RDN对HFpEF患者的长期影响需要进一步研究.
研究的目的:
- 在被诊断为心力衰竭与保留射出小部分 (HFpEF) 的患者中研究交感性缩 (RDN) 的长期影响.
- 在9年的随访期内评估RDN对HFpEF标准的影响,包括心声和生物标志物评估.
主要方法:
- 从2011年至2014年期间接受高频RDN的当地RDN注册表的患者进行了跟踪.
- 评估包括24小时的门诊血压监测,胸前心声学和实验室测试.
- 使用心脏衰竭协会 (HFA) -PEFF评分,利用心声和生物标志物标准,用于识别和评估HFpEF.
主要成果:
- 在9年的随访期间,70名患者的心声图数据显示,有21名患者具有HFpEF.
- 观察到HFA-PEFF得分显著下降,从基线时的5.48 ± 0.51降至9年后的4.33 ± 1.53 (P < 0.01).
- 这一下降主要是由于形态和生物标记子类别的改善,这表明左心室缩和左心房扩张减少.
结论:
- 同情性缩 (RDN) 可能导致心力衰竭的回归,除了降低血压的作用之外,还保留了喷射分数 (HFpEF).
- RDN可能有助于改善HFpEF患者的预后.
- 预计从正在进行的随机化模拟受控试验中得到进一步的见解.
更多相关视频
07:13A Rat Model of Pressure Overload Induced Moderate Remodeling and Systolic Dysfunction as Opposed to Overt Systolic Heart Failure
Published on: April 30, 2020
6.4K
07:49Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
1.3K
相关概念视频
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
419
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
419
Heart Failure Drugs: Diuretics
362
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
362
Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
